Owners, management and financials
CVR: 38402056
Previous names: Antag Therapeutics IVS
DKK -191,588,449
Gross profit
Net result: DKK -200,999,582
Novo Holdings A/S (20-24,99%), Dawn Holdco SCSp (10-14,99%)
2 more
CVR · view owners
Philip Just Larsen
Board: Keith Richard Leonard Jr (chair) and 5 members
CVR · view management
Active
Founded 8 February 2017
CVR · view overview
6 employees
CVR · 2018
Owner registered: Novo Holdings A/S
CVR · 08/04/2026
View the full event history
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 6 employees (2018). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.
Selskabets formål er forskning og udvikling af lægemidler samt dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -191.6 mio. | -201 mio. | 28 mio. | 235 t. | 10 | |
| 202401/01/2024 – 31/12/2024 | -30.6 mio. | -32.3 mio. | 225.4 mio. | 201.2 mio. | 2 | |
| 202301/01/2023 – 31/12/2023 | -13.7 mio. | -13.8 mio. | 24 mio. | -9.2 mio. | 2 | |
| 202201/01/2022 – 31/12/2022 | -9.9 mio. | -9.8 mio. | 17.6 mio. | 4.6 mio. | 2 | |
| 202101/01/2021 – 31/12/2021 | -13.1 mio. | -14.9 mio. | 20.7 mio. | 10.9 mio. | 6 | |
| 202001/01/2020 – 31/12/2020 | -10.9 mio. | -12.4 mio. | 15.7 mio. | -9.8 mio. | 7 | |
| 201901/01/2019 – 31/12/2019 | -7.9 mio. | -9.2 mio. | 14.1 mio. | 2.6 mio. | 4 | |
| 201801/01/2018 – 31/12/2018 | -3.1 mio. | -4.4 mio. | 12.7 mio. | 11.8 mio. | 4 | |
| 201708/02/2017 – 31/12/2017 | -3.7 mio. | -3.9 mio. | 10.1 mio. | 8.7 mio. | 2 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Antag Therapeutics ApS is 38402056.
The owners of Antag Therapeutics ApS include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P..
The management of Antag Therapeutics ApS consists of Philip Just Larsen.
The board of Antag Therapeutics ApS consists of Keith Richard Leonard Jr, Alexander Volker Wilhelm Mayweg and Amit Kantilal Shah, with Keith Richard Leonard Jr as chair.
In 2025, Antag Therapeutics ApS reported a gross profit of DKK -191,588,449.
Antag Therapeutics ApS had 6 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Antag Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -191,588,449, and the net result was DKK -200,999,582.
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (June 9, 2026).
As of June 8, 2026, Jørgen Søberg Petersen has joined the board of directors of Antag Therapeutics ApS.
As of June 8, 2026, Keith Richard Leonard Jr has joined the board of directors of Antag Therapeutics ApS.
As of June 7, 2026, Jørgen Søberg Petersen has left the board of directors of Antag Therapeutics ApS.
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (May 6, 2026).
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (April 17, 2026).
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (April 16, 2026).
As of April 8, 2026, Jørgen Søberg Petersen has joined the board of directors of Antag Therapeutics ApS.
As of April 8, 2026, Novo Holdings A/S is registered as an owner of Antag Therapeutics ApS with an ownership share of 20%.
As of April 8, 2026, is registered as an owner of Antag Therapeutics ApS with an ownership share of 10%.
As of April 8, 2026, is registered as an owner of Antag Therapeutics ApS with an ownership share of 25%.
As of April 8, 2026, is registered as an owner of Antag Therapeutics ApS with an ownership share of 5%.
As of April 7, 2026, Jørgen Søberg Petersen has left the board of directors of Antag Therapeutics ApS.
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (April 1, 2026).
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (March 31, 2026).
As of March 31, 2026, Jörg Möller has left the board of directors of Antag Therapeutics ApS.
As of March 31, 2026, Philip Just Larsen is registered as adm. dir. of Antag Therapeutics ApS.
As of March 31, 2026, Jörg Möller has stepped down as adm. dir. of Antag Therapeutics ApS.
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (February 20, 2026).
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (January 20, 2026).
Contact info changed: new phone: 21456537, new email: [email protected], new website: http://www.antagtherapeutics.com/ (January 19, 2026).
Antag Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -30,596,301, and the net result was DKK -32,265,249.
As of January 28, 2025, Jörg Möller has joined the board of directors of Antag Therapeutics ApS.
As of January 28, 2025, Alexander Hovard Sparre-Ulrich has left the board of directors of Antag Therapeutics ApS.
As of January 6, 2025, Jörg Möller is registered as adm. dir. of Antag Therapeutics ApS.
As of January 6, 2025, Alexander Hovard Sparre-Ulrich has stepped down as adm. dir. of Antag Therapeutics ApS.
As of November 5, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of Antag Therapeutics ApS.
As of November 5, 2024, KPMG P/S has stepped down as auditor of Antag Therapeutics ApS.
As of November 5, 2024, Jørgen Søberg Petersen has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Alexander Hovard Sparre-Ulrich has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Amit Kantilal Shah has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Alexander Volker Wilhelm Mayweg has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Jens Juul Holst has left the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Pieter Jeroen Bakker has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -13,707,565, and the net result was DKK -13,811,394.
As of September 13, 2023, Jayson Dallas has left the board of directors of Antag Therapeutics ApS.
As of September 12, 2023, Thomas Edward Needham Jr. has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -9,904,462, and the net result was DKK -9,784,355.
As of June 1, 2023, Mark Currie has joined the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Jayson Dallas has joined the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Kirsten Aarup Drejer has left the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Christine Theresa Fischette has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -13,085,955, and the net result was DKK -14,863,343.
Antag Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -10,925,243, and the net result was DKK -12,353,317.
As of June 28, 2021, Christine Theresa Fischette has joined the board of directors of Antag Therapeutics ApS.
As of December 31, 2020, Anker Gunvald Lundemose has left the board of directors of Antag Therapeutics ApS.
As of September 2, 2020, Emmanuelle Coutanceau has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK -7,866,664, and the net result was DKK -9,232,193.
As of March 11, 2020, Pieter Jeroen Bakker has joined the board of directors of Antag Therapeutics ApS.
As of March 11, 2020, Thomas Edward Needham Jr. has joined the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2018. Gross profit came to DKK -3,123,509, and the net result was DKK -4,429,240.
As of September 28, 2018, Philip Just Larsen has joined the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its interim report for the period February 8, 2017 – December 31, 2017.
As of May 31, 2017, Kirsten Aarup Drejer has joined the board of directors of Antag Therapeutics ApS.
As of May 31, 2017, Anker Gunvald Lundemose has joined the board of directors of Antag Therapeutics ApS.
As of May 31, 2017, Emmanuelle Coutanceau has joined the board of directors of Antag Therapeutics ApS.
As of May 31, 2017, Jens Juul Holst has joined the board of directors of Antag Therapeutics ApS.
As of May 30, 2017, KPMG P/S has been appointed auditor of Antag Therapeutics ApS.
On May 30, 2017, the company changed its name from Antag Therapeutics IVS to Antag Therapeutics ApS.
As of February 8, 2017, Alexander Hovard Sparre-Ulrich is registered as adm. dir. of Antag Therapeutics ApS.
Antag Therapeutics ApS was founded on February 8, 2017.
Companies in the same industry and area
CVR 39859173
CVR 39880377
CVR 42057428
CVR 43432583
CVR 43575627
